Simcere Pharmaceutical Group has launched a research collaboration with Stanford Medicine to develop potential first-in-class therapies for idiopathic pulmonary fibrosis (IPF), a progressive and life-threatening lung disease. Under this agreement announced on June 15, 2026, Simcere Pharmaceutical Group funds early
